Amicus Therapeutics has raised $55 million in its third round of venture capital and simultaneously announced it would launch a mid-stage trial of its lead drug candidate following the successful conclusion of Phase I. Quaker BioVentures led the round. Amicus has been focusing much of its attention on Amigal, an experimental drug for Fabry disease. Amicus' second product candidate, AT2101, a treatment for Gaucher disease, is in late stage preclinical development with clinical trials expected to commence in the first half of 2006.

- read this press release for more

ALSO: Replidyne of Louisville, Colorado, has garnered $62.5 million in its fourth venture round. Replidyne's lead product, faropenem medoxomil, is an oral antibiotic for a community of infections such as respiratory tract infections. Release